Antithrombotic Strategy for AF Patients With High Risk CAD

NCT ID: NCT06866665

Last Updated: 2025-03-14

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 1400 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-31
• Study Completion Date: 2030-12-31

Brief Summary

Anticoagulation therapy is recommended for patients with atrial fibrillation (AF) in order to prevent ischemic stroke and systemic embolism. Meanwhile, lifelong antiplatelet therapy is highly recommended to prevent stent thrombosis and further ischemic adverse events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. In this context, in patients with AF undergoing DES implantation, anticoagulation and antiplatelet therapies perform their own unique roles. However, the current guidelines recommend to discontinue this antiplatelet agent beyond 1 year due to an excessive bleeding risk derived from DAT.

The Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) emphasized that bleeding risk derived from rivaroxaban-based DAT may outweigh ischemic risk derived from antiplatelet discontinuation in patients with AF and stable coronary artery disease. Furthermore, the recent Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease (EPIC-CAD) trial also demonstrated that edoxaban monotherapy led to a lower net adverse event compared to than edoxaban-based DAT.

Although these studies strongly supported the benefit of antiplatelet discontinuation in AF patients with stable coronary artery disease, many physicians still hesitate to discontinue antiplatelet agents even 1 year after DES implantation because of concerns regarding stent thrombosis or subsequent myocardial infarction (MI). This concern is exacerbated in patients with an excessive ischemic risk, such as those who received complex PCI or those with polyvascular disease. To address this disparity between clinical practice and recommendations based on the guidelines, the Adequate Antiplatelet and Anticoagulation Therapy in Atrial Fibrillation Patients with Focus on Ischemic Risk Management (ADAPT AFFIRM) trial is designed to elucidate the efficacy and safety of apixaban monotherapy versus apixaban plus clopidogrel combination therapy as a chronic maintenance strategy in AF patients with stable coronary artery disease and excessive ischemic risk.

Detailed Description

Investigators will recruit 1400 patients with atrial fibrillation (AF) and coronary artery disease (CAD) with high ischemic risk. High ischemic risk is defined as acute myocardial infarction, complex percutaneous coronary intervention (PCI), untreated significant coronary stenosis, or polyvascular disease. Paticipants will be randomly assigned to either anticoagulation monotherapy group or combination therapy group. Participants assigned to the anticoagulation monotherapy group wil receive apixaban 5 mg twice daily (or reduced dose as judged by investigators) and those assigned to the combination therapy group will receive additional clopidogrel 75 mg daily on top of apixaban. Net adverse clinical events comprising all-cause death, myocardial infarction, stroke, systemic embolism, or ISTH major or clinically relevant non-major bleeding events will be evaluated at 12 months after randomization. Included participant will be followed up until the last participant will be followed up for at lease 12 months.

Conditions

Atrial Fibrillation; Coronary Artery Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Anticoagulation Monotherapy

Participants receiving anticoagulation monotherapy

Group Type: ACTIVE_COMPARATOR

Anticoagulation Monotherapy

Intervention Type: DRUG

Participants in the anticoagulation monotherapy group will receive apixaban 5 mg twice daily during the study period.

Combination therapy

Particiapnts receiving anticoagulation therapy with additional clopidogrel

Group Type: EXPERIMENTAL

Combination therapy

Intervention Type: DRUG

Participants in the combination therapy group will receive clopiogrel 75 mg daily and apixaban 5 mg twice daily during the study period.

Interventions

Anticoagulation Monotherapy

Participants in the anticoagulation monotherapy group will receive apixaban 5 mg twice daily during the study period.

Intervention Type: DRUG

Combination therapy

Participants in the combination therapy group will receive clopiogrel 75 mg daily and apixaban 5 mg twice daily during the study period.

Intervention Type: DRUG

Other Intervention Names

Apixaban monotherapy; Apixaban and clopidogrel combination therapy

Eligibility Criteria

Inclusion Criteria

1. ≥ 19 years old

2. Presence of AF with CHA2DS2-VASc score ≥ 2

3. Patients with stable CAD - a history of percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) before 6 months (chronic coronary syndrome) or 12 months (acute coronary syndrome); anatomically confirmed CAD on coronary angiography or computed tomography scan

4. Presence of an excessive ischemic risk i. A history of myocardial infarction (MI) ii. Complex PCI iii. Untreated lesion with >50% stenosis at major epicardial vessel after coronary revascularization iv. Untreated multivessel CAD (>50% stenosis of >1 major epicardial vessel or left main stem) v. Peripheral artery disease vi. Cerebrovascular disease

Exclusion Criteria

1. >85 years old.

2. Patients who received PCI or CABG within 6 months.

3. Patients with a history of acute coronary syndrome within 12 months.

4. Patients who require anticoagulation with warfarin due to a mechanical prosthetic valve, or ≥ moderate mitral stenosis.

5. Patients with a comorbidity requiring anticoagulation other than AF.

6. Patients who is not able to receive apixaban or clopidogrel due to previous adverse reaction.

7. Patients who have coagulopathy or have a history of recurrent bleeding.

8. Intracranial or gastrointestinal bleeding within 3 months.

9. Gastrointestinal tumor requiring treatment.

10. Patients who are pregnant or those who report potential pregnancy.

11. Life expectancy < 1 year due to malignancy.

12. Refuse or enable to understand the written informed consent.

13. Patiens who are not able to discontinue a drug related to CYP3A4 inhibition.

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Yonsei University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

jung sun Kim, MD,PhD

Role: CONTACT

KJS1218@yuhs.ac

+82-2-2228-8457

Other Identifiers

4-2024-1325

Identifier Type: -

Identifier Source: org_study_id